Results of a Phase II Study of Cladribine, Low Dose Cytarabine and Venetoclax, Alternating with Azacitidine and Venetoclax in Patients with Higher Risk Chronic Myelomonocytic Leukemia or Myelodysplastic Syndromes

被引：0

作者：

Montalban-Bravo, Guillermo ^{[1
]}

Short, Nicholas J. ^{[1
]}

Chien, Kelly S. ^{[1
]}

Valero, Yesid Alvarado ^{[1
]}

Daver, Naval ^{[1
]}

Borthakur, Gautam ^{[1
]}

Swaminathan, Mahesh ^{[1
]}

Maiti, Abhishek ^{[2
]}

Hammond, Danielle E. ^{[1
]}

Nogueras-Gonzalez, Graciela ^{[3
]}

Huang, Xuelin ^{[3
]}

Schneider, Heather ^{[4
]}

Shelly, Kristen ^{[4
]}

Kadia, Tapan M. ^{[1
]}

Kantarjian, Hagop M. ^{[4
]}

Garcia-Manero, Guillermo ^{[5
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA

[2] MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA

[3] Univ Texas MD Anderson Canc Ctr, Biostat, Houston, TX USA

[4] Univ Texas MD Anderson Canc Ctr, Leukemia, Houston, TX USA

[5] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-178035

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[41] Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
Kantarjian, Hagop
Oki, Yasuhiro
Garcia-Manero, Guillermo
Huang, Xuelin
O'Brien, Susan
Cortes, Jorge
Faderl, Stefan
Bueso-Ramos, Carlos
Ravandi, Farhad
Estrov, Zeev
Ferrajoli, Alessandra
Wierda, William
Shan, Jianqin
Davis, Jan
Giles, Francis
Saba, Hussain I.
Issa, Jean-Pierre J.
BLOOD, 2007, 109 (01) : 52 - 57
[42] Predictive Model for Infection Risk in Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Patients Treated With Azacitidine; Azacitidine Infection Risk Model: The Polish Adult Leukemia Group Study
Madry, Krzysztof
Lis, Karol
Biecek, Przemyslaw
Mlynarczyk, Magda
Rytel, Agoda
Gorka, Michal
KacFrzyk, Piotr
Dutka, Magdalena
Rodzaj, Marek
Bolkun, Lukasz
Krochmalczyk, Dorota
Latka, Ewa
Drozd-Sokolowska, Joanna
Waszczuk-Gajda, Anna
Knopinska-Posluszny, Wanda
Kopinska, Anna
Subocz, Edyta
Masternak, Anna
Guzicka-Kazimierczak, Renata
Gil, Lidia
Machowicz, Rafal
Bilinski, Jaroslaw
Giebe, Sebastian
Czerw, Tomasz
Dwilewicz-Trojaczek, Jadwiga
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (05) : 264 - +
[43] Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study
Sallman, David A.
Al Malki, Monzr M.
Asch, Adam S.
Wang, Eunice S.
Jurcic, Joseph G.
Bradley, Terrence J.
Flinn, Ian W.
Pollyea, Daniel A.
Kambhampati, Suman
Tanaka, Tiffany N.
Zeidner, Joshua F.
Garcia-Manero, Guillermo
Jeyakumar, Deepa
Komrokji, Rami
Lancet, Jeffrey
Kantarjian, Hagop M.
Gu, Lin
Zhang, Yajia
Tan, Anderson
Chao, Mark
O'Hear, Carol
Ramsingh, Giridharan
Lal, Indu
Vyas, Paresh
Daver, Naval G.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (15) : 2815 - +
[44] Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
Kantarjian, Hagop M.
Oki, Yasuhiro
Issa, Jean-Pierre
BLOOD, 2006, 108 (13) : 4291 - 4292
[45] Venetoclax Combined with Cladribine, Idarubicin, Cytarabine (CLIA) As Induction Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
Reville, Patrick K.
Kantarjian, Hagop
Borthakur, Gautam
Yilmaz, Musa
Daver, Naval
Short, Nicholas
DiNardo, Courtney D.
Kornblau, Steven M.
Pemmaraju, Naveen
Jain, Nitin
Alvarado, Yesid
Bose, Prithviraj
Jabbour, Elias
Chien, Kelly S.
Abbas, Hussein A.
Masarova, Lucia
Wang, Sa A.
Tidwell, Rebecca S. S.
Andreeff, Michael
Garcia-Manero, Guillermo
Konopleva, Marina
Ravandi, Farhad
Kadia, Tapan M.
BLOOD, 2022, 140 : 1702 - 1704
[46] Results of 5-azacitidine therapy in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML)
Freyrie, A.
Reda, G.
Vincenti, D.
Ferla, V.
Orofino, N.
Sciume, M.
Guidotti, F.
Cortelezzi, A.
LEUKEMIA RESEARCH, 2013, 37 : S157 - S158
[47] Lemzoparlimab (lemzo) with venetoclax (ven) and/or azacitidine (aza) in patients (pts) with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS): A phase 1b dose escalation study.
Daver, Naval Guastad
Stevens, Don A.
Hou, Jing-Zhou
Yamauchi, Takahiro
Moshe, Yakir
Fong, Chun Yew
Marzocchetti, Angela
Adamec, Ryan
Patel, Maulik
Lambert, Stacie
Wu, Kevin
Rollig, Christoph
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[48] Azacitidine-eligibility in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukaemia: a registry-based study
Durairaj, Senthilkumar
Keenan, Norene
Hyslop, Ann
Groves, Michael J.
Bowen, David T.
Tauro, Sudhir
BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 (02) : 280 - 282
[49] Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117
Sekeres, Mikkael A.
Othus, Megan
List, Alan F.
Odenike, Olatoyosi
Stone, Richard M.
Gore, Steven D.
Litzow, Mark R.
Buckstein, Rena
Fang, Min
Roulston, Diane
Bloomfield, Clara D.
Moseley, Anna
Nazha, Aziz
Zhang, Yanming
Velasco, Mario R.
Gaur, Rakesh
Atallah, Ehab
Attar, Eyal C.
Cook, Elina K.
Cull, Alyssa H.
Rauh, Michael J.
Appelbaum, Frederick R.
Erba, Harry P.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (24) : 2745 - +
[50] Phase II study of pevonedistat (P) plus azacitidine (A) versus A in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML), or low-blast acute myelogenous leukemia (LB AML) (NCT02610777).
Ades, Lionel
Watts, Justin M.
Radinoff, Atanas
Arnan, Montserrat
Cerrano, Marco
Font Lopez, Patricia
Zeidner, Joshua F.
Diez-Campelo, Maria
Graux, Carlos
Liesveld, Jane
Selleslag, Dominik
Tzvetkov, Nikolay
Fram, Robert J.
Zhao, Dan
Faller, Douglas, V
Sekeres, Mikkael A.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

← 1 2 3 4 5 →